Flavio Fontes Pirozzi and Marco Antonio Fernandes Dias
According to epidemiological data on type 2 diabetes (T2DM) represents about 95 % of cases of diabetes diagnosed, with projected to exceed 480 million in 2030. In addition, pulmonary arterial hypertension (PAH) has an estimated prevalence of 30 to 50 cases per million population, affects women more often than men, and PAH and T2DM are medical conditions that presents statistical correlation. The aim of this study was to evaluate the treatment in patients with diabetic that despite age, reported no episodes of hypoglycemia during the case study. Larger studies are needed to assess whether the same results are reproducible in diabetics and also euglycemic patients with PAH. Case 1, SPLM, patient 63-year-old female with a previous diagnosis of T2DM, obesity, hypertension and dyslipidemia forwarded to endocrine evaluation for better glycemic control and weight loss. Case 2, HFC,patient 74-year-old female with a previous diagnosis of T2DM about three years, obesity, hypertension, dyslipidemia osteopenia, vitamin D deficiency and pulmonary hypertension. In the present study, this is the first description in humans that use a iDDP4 may be a treatment option for patients with PAH by the presence of receptor GLP-1R in the lung. It was concluded that in the first case there was weight loss and improved glycemic level. In the second case, both the glucose level of the weight remained. In both cases, using vildagliptin, there was a decrease in systolic pressure of right ventricle pointed out that the relaxation of pulmonary artery has a more beneficial effect would be mediated by NO and activation of vascular potassium channels, further of the effect direct by increasing GLP1, since the IRS1 less inhibited increases the activation of kinases, which in turn increases the stimulus for nitric oxide production in endothelial cells, reducing pulmonary arterial pressure.
